Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China
The Pharma Data
JUNE 24, 2025
A recent example is Bayer’s global license agreement with Puhe BioPharma , focused on an oral, small molecule PRMT5 inhibitor designed to selectively target MTAP-deleted tumors. This agreement grants Bayer exclusive global rights to develop, manufacture, and commercialize the MTA-cooperative PRMT5 inhibitor.
Let's personalize your content